SKI-178

• CAT Number: I009511
• CAS Number: 1259484-97-3
• Molecular Formula: C21H22N4O4
• Molecular Weight: 394.43
• Purity: ≥95%
• Synonyms: SKI-178; SKI 178; SKI178.;N/’-(1-(3,4-Dimethoxyphenyl)ethylidene)-3-(4-methoxyphenyl)-1H-pyrazole-5-carbohydrazide
• Target: Apoptosis
• Solubility: Soluble in DMSO
• Storage: 0 - 4 °C for short term, or -20 °C for long term
• IUPAC Name: N-[(E)-1-(3,4-dimethoxyphenyl)ethylideneamino]-3-(4-methoxyphenyl)-1H-pyrazole-5-carboxamide
• InChI: InChI=1S/C21H22N4O4/c1-13(15-7-10-19(28-3)20(11-15)29-4)22-25-21(26)18-12-17(23-24-18)14-5-8-16(27-2)9-6-14/h5-12H,1-4H3,(H,23,24)(H,25,26)/b22-13+
• InChIKey: GMFUWEBOUKIKRP-LPYMAVHISA-N
• SMILES: CC(=NNC(=O)C1=CC(=NN1)C2=CC=C(C=C2)OC)C3=CC(=C(C=C3)OC)OC

SKI-178 (CAT: I009511) is indeed a sphingosine kinase 1 (SphK1) inhibitor, with an IC50 range of 0.1-1.8 μM. It induces prolonged mitosis followed by apoptotic cell death through the intrinsic apoptotic cascade. The sustained activation of CDK1 during prolonged mitosis, mediated by SKI-178, leads to the simultaneous phosphorylation of the prosurvival Bcl-2 family members, Bcl-2 and Bcl-xl, as well as the phosphorylation and subsequent degradation of Mcl-1. SKI-178 shows promise as a novel therapeutic agent for the treatment of acute myeloid leukemia (AML), including multidrug-resistant/recurrent AML subtypes.